News Releases

Patient Care

We deliver high-quality care with innovation and empathy.

GO TO ALL PATIENT CARE

Kidney Care

Vascular Access Care

Integrated Renal Care

Laboratory & Diagnostic Services

Renal Pharmacy

We deliver high-quality care with innovation and empathy.

GO TO ALL PRACTICE SUPPORT

Practice Management

Practice Technology

Cardiology Lab Partnerships

Renal Research

Frenova Renal Research

Renal Research Institute

Physician Recruitment

Apheresis Services

PRACTICE SUPPORT

Products

Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.

GO TO ALL PRODUCTS

2008T BlueStar Hemodialysis Machine

AquaBplus

AquaC UNO H

GO TO ALL IN-CENTER DIALYSIS EQUIPMENT

2008k@home Machine

NxStage System One S

Liberty Select Cycler

stay • safe System

GO TO ALL HOME DIALYSIS PRODUCTS

NxStage System One S with NxView

Novalung

GO TO ALL CRITCAL CARE

Crit-Line lll Monitor

Crit-Line lV Monitor

CLiC Device

GO TO ALL FLUID MANAGEMENT

Dialyzers

Concentrates

Bloodlines

GO TO ALL DISPOSABLES

Venofer

Velphoro

Phoslyra

GO TO ALL PHARMACEUTICALS

Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.

GO TO ALL INSIGHTS

Insights

Insights Hub

Research and Innovation

Home Dialysis

Value Based Care

Our Impact

GO TO ALL INSIGHTS HUB

Global Annual Medical Report

Field Notes Podcast

Global Medical Office Dialogues

Our Company

Our Company

Overview

Mission, Vision & Values

Corporate Responsibility

Supplier Information

News Releases

Kidney Week 2021: FMCNA Commits to Improving Dialysis Care

FMCNA on Newsweek List of Most Loved Workplaces in 2021

FMCNA Announces Three Key Leadership Appointments

Embracing the Complexity of Global Healthcare

Dialysis Nurse Residency Program

Fresenius Medical Care Celebrates 25th Anniversary

80% of NxStage Home Dialysis Patients Use Nx2me Health Platform

Fresenius Medical Care increases investment in Humacyte